For more information or confidential assistance
se habla español

Study Examines Testosterone Dosage and Heart Risks

In July, researchers from the University of North Carolina at Chapel Hill published a study on testosterone heart risks in the medical journal, JAMA Internal Medicine, finding that the side effects of testosterone injections may pose the highest risk of cardiovascular events, hospitalizations and deaths. The team examined the comparative... Read more »

Report Highlights Diabetic Ketoacidosis Risk Factors for SGLT2 Inhibitor Patients

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

AndroGel Testosterone Lawsuits to Proceed as Planned

District Judge Matthew Kennelly, who is overseeing 1,500 AndroGel testosterone lawsuits in federal court, has denied a request by Abbvie, the manufacturer of AndroGel, to amend the schedule for a group of bellwether trials to be held in 2016 and 2017. Abbvie specifically requested that the court allow expert discovery and summary... Read more »

Phoenix Residents File Actos Lawsuit Over Bladder Cancer

A number of plaintiffs from Tucson, AZ have filed an Actos lawsuit against Takeda Pharmaceuticals citing personal injury, wrongful death and/or loss of consortium. They claim that use of the drug caused them to develop bladder cancer. Their lawsuits will be added to the ongoing multidistrict litigation in Louisiana. Actos,... Read more »

New Class of Diabetes Drugs Subject of FDA Warning

Less than two weeks ago, the FDA released an important drug safety communication regarding a new class of diabetes drugs, including those marketed under the brand names Invokana, Farxiga and Jardiance. Health regulators caution that diabetic patients taking this class of sodium-glucose cotransporter-2 (SGLT2) inhibitors may be at risk for... Read more »

Jury Awards $15 Million in Depakote Birth Defects Case

A Minnesota family filed a Depakote lawsuit against drugmaker Abbott, alleging that the defendants failed to properly communicate the serious risks of using the drug during pregnancy – which is similar to claims made in lawsuits filed with regard to the dangers of Zofran use during pregnancy. The child, a 12-year-old... Read more »